XOMA Royalty Corporation (NASDAQ:XOMA) Receives Average Rating of “Hold” from Analysts

Shares of XOMA Royalty Corporation (NASDAQ:XOMA) have earned a consensus recommendation of “Hold” from the seven research firms that are currently covering the firm, MarketBeat reports. Six investment analysts have rated the stock with a hold rating and one has issued a buy rating on the company. The average 1 year price objective among analysts that have issued ratings on the stock in the last year is $53.75.

XOMA has been the topic of a number of research reports. Lucid Cap Mkts cut XOMA Royalty from a “strong-buy” rating to a “hold” rating in a research note on Monday, April 27th. Weiss Ratings raised XOMA Royalty from a “hold (c-)” rating to a “hold (c)” rating in a research note on Friday, May 29th. HC Wainwright downgraded XOMA Royalty from a “buy” rating to a “neutral” rating and set a $39.00 price objective on the stock. in a report on Thursday, April 30th. Finally, Benchmark lowered XOMA Royalty from a “buy” rating to a “hold” rating in a research note on Friday, May 22nd.

Institutional Trading of XOMA Royalty

A number of institutional investors and hedge funds have recently bought and sold shares of XOMA. State of Alaska Department of Revenue purchased a new position in shares of XOMA Royalty in the fourth quarter valued at approximately $27,000. Russell Investments Group Ltd. increased its stake in XOMA Royalty by 3,436.4% during the 3rd quarter. Russell Investments Group Ltd. now owns 778 shares of the biotechnology company’s stock worth $30,000 after buying an additional 756 shares during the period. Tower Research Capital LLC TRC increased its stake in XOMA Royalty by 203.1% during the 2nd quarter. Tower Research Capital LLC TRC now owns 2,273 shares of the biotechnology company’s stock worth $57,000 after buying an additional 1,523 shares during the period. JPMorgan Chase & Co. lifted its holdings in XOMA Royalty by 13.9% during the 2nd quarter. JPMorgan Chase & Co. now owns 4,440 shares of the biotechnology company’s stock worth $112,000 after buying an additional 543 shares in the last quarter. Finally, Raymond James Financial Inc. acquired a new stake in XOMA Royalty during the 2nd quarter worth approximately $116,000. 95.92% of the stock is currently owned by hedge funds and other institutional investors.

XOMA Royalty Stock Performance

Shares of XOMA stock opened at $40.17 on Tuesday. The firm’s 50 day moving average price is $41.31 and its 200-day moving average price is $36.16. The company has a debt-to-equity ratio of 0.96, a quick ratio of 3.59 and a current ratio of 3.59. XOMA Royalty has a one year low of $22.29 and a one year high of $45.22. The firm has a market cap of $503.77 million, a P/E ratio of 25.59 and a beta of 0.86.

XOMA Royalty (NASDAQ:XOMA) last posted its quarterly earnings data on Tuesday, May 12th. The biotechnology company reported $0.17 earnings per share for the quarter, missing analysts’ consensus estimates of $0.19 by ($0.02). XOMA Royalty had a return on equity of 12.56% and a net margin of 53.46%.The company had revenue of $12.32 million for the quarter, compared to analysts’ expectations of $13.91 million. As a group, equities research analysts predict that XOMA Royalty will post 0.9 EPS for the current year.

XOMA Royalty Company Profile

XOMA Royalty (NASDAQ: XOMA) is a specialty healthcare royalty company that acquires and manages royalty interests in small-molecule and biologic drugs. The company’s business model centers on purchasing royalty streams on marketed or near-market pharmaceutical products, providing capital to developers in exchange for a share of future net sales. By focusing on late-stage assets with established clinical and commercial profiles, XOMA Royalty aims to generate predictable, long-term cash flows for its shareholders.

The company’s investment portfolio spans a range of therapeutic areas, including oncology, immunology and rare diseases.